Brainsway (BWAY)

• Market cap: $206M
• 1 day: -4.55%
• 5 days: 2.73%
• 1 month: 11.11%
• 3 months: 6.76%
• 6 months: 15.71%
• Year to date: 13.78%
• 1 year: 75.52%
• 5 years: 56.83%
• 10 years: -1.71%
• Sector: Healthcare
• Industry: Medical Devices

About: BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Employees: 120

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

8% more funds holding

Funds holding: 39 [Q4 2024] → 42 (+3) [Q1 2025]

1% more capital invested

Capital invested by funds: $56.1M [Q4 2024] → $56.7M (+$557K) [Q1 2025]

0.05% more ownership

Funds ownership: 15.81% [Q4 2024] → 15.86% (+0.05%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

8% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 12

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $16 47% upside
• Avg. target: $16 47% upside
• High target: $16 47% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju

47% upside $16

Buy Reiterated

12 Jun 2025